Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
You might also like
  • Save
Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Bosutinib FDA approved for the treatment of patients with newly-diagnosed chronic phase Ph+ CML
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Brentuximab vedotin FDA approved for pre-treated primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)
  • Save
Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation
FDA approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). More Information.  July 13, 2018
  • Save
Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
More Information.  June 19, 2018">
  • Save
More Information.  June 19, 2018" alt="FDA  has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.  More Information.  June 19, 2018" height="180" width="180" srcset="https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-180x180.jpg 180w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-80x80.jpg 80w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-36x36.jpg 36w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-120x120.jpg 120w, https://medi-paper.com/wp-content/uploads/2018/07/FDA-has-limited-the-use-of-Tecentriq-and-Keytruda-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer-who-are-not-eligible-for-cisplatin-containing-therapy.-More-Information-.-June-19-2018-e1537925445648-450x450.jpg 450w" sizes="(max-width: 180px) 100vw, 180px"> FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply